Elis combines recurring, defensible rental-services cash flows and European route-density leadership with a discounted 6.27x EV/EBITDA valuation and a probability-weighted five-year target of €40.20.
Elis SA is an international multiservice provider specializing in circular, eco-responsible rental and maintenance solutions for flat linen, workwear, hygiene, wellness, cleanroom, and pest control services [cite: 1, 2, 3]. Headquartered in France, the group operates across 30 countries in Europe and Latin America, utilizing a network of over 460 industrial laundry plants and distribution centers serving approximately 400,000 enterprise customers [cite: 4, 5].
The group's operational model centers on a circular economy framework: Elis purchases, rents, cleans, repairs, and delivers reusable textile and hygiene assets, allowing business clients to outsource capital-intensive and operationally complex facility and linen management [cite: 6, 7]. Revenue is generated through long-term, multi-year service contracts—typically three to five years in duration—comprising fixed recurring rental fees combined with variable maintenance and laundering charges based on delivery volume [cite: 8].
| Business Dimension | Operational Detail | Strategic Focus |
|---|---|---|
| Product & Service Lines | Flat linen, workwear, cleanrooms, hygiene dispensers, pest control | Asset reuse, circular economy, turnkey logistics [cite: 1, 3, 6] |
| Primary End Markets | Healthcare, Hospitality, Industry, Trade & Services | High recurring demand, regulatory compliance [cite: 2, 9] |
| Geographic Footprint | France, Central Europe, Scandinavia, UK/Ireland, Southern Europe, LatAm | Network density, local market consolidation [cite: 2, 6] |
| Value Proposition | CapEx elimination, guaranteed hygiene standards, lower carbon footprint | High switching costs, operational peace of mind [cite: 6, 7, 10] |
Elis serves four core customer segments:
Geographically, revenue is distributed across key business regions: France, Central Europe, Scandinavia & Eastern Europe, the United Kingdom & Ireland, Southern Europe, and Latin America [cite: 2, 6]. Customers select Elis over local or in-house alternatives due to four primary factors: significant reduction in upfront capital expenditure, guaranteed compliance with stringent health and environmental regulations, regional plant density that ensures supply chain continuity, and measurable carbon footprint reductions achieved through industrial-scale water and energy efficiency in laundering operations [cite: 6, 7, 8].
Elis operates a capital-intensive, density-driven business model that yields high operating margins when scaled across dense geographic delivery routes [cite: 6, 10]. The primary economic engine relies on maximizing route density—minimizing the distance driven and time spent per delivery stop by clustering customer contracts around localized industrial laundering facilities [cite: 10].
| Category | Key Product Offerings | Operational & Logistics Mechanism |
|---|---|---|
| Workwear & Cleanrooms | Protective garments, flame-retardant wear, cleanroom suits | Microchip/RFID tracking, industrial washing, localized repairs [cite: 1, 2, 3, 6] |
| Flat Linen | Bed sheets, pillowcases, bath towels, table linens | High-volume industrial laundering, automated ironing, rigid delivery [cite: 2, 6, 7] |
| Hygiene & Facilities | Floor mats, touchless dispensers, pest control, water units | Periodic maintenance, replacement cycles, cross-selling focus [cite: 1, 2, 3] |
Workwear offerings include tailored work garments, high-visibility clothing, chemical-resistant suits, and ultra-clean protective wear used in semiconductor and pharmaceutical manufacturing [cite: 1, 3, 6]. Individual garments are outfitted with microchips or RFID tags to track laundering lifecycles, repairs, and localized distribution to specific employees [cite: 2, 3]. Flat linen offerings encompass high-volume sheets, pillowcases, bath towels, and table linen owned by Elis, laundered at high-temperature industrial sites, and delivered on rigid schedules [cite: 2, 6, 7]. Hygiene, pest control, and floor care lines include ergonomic floor mats, touchless soap dispensers, hand-drying units, air fresheners, and integrated pest management systems, representing high-margin cross-selling opportunities across the existing client base [cite: 1, 2, 3].
Elis possesses a robust, multi-layered economic moat characterized by high switching costs, localized scale advantages, and substantial capital barriers to entry [cite: 10].
| Moat Component | Key Structural Driver | Economic Advantage |
|---|---|---|
| Switching Costs | Multi-year contracts, integrated RFID inventories | High operational friction and service disruption risk upon switching [cite: 8, 10] |
| Scale & Route Density | 460+ plants, route optimization | Lowest marginal delivery cost per customer stop in core markets [cite: 4, 10] |
| Capital Intensity | High capital requirement for modern facilities | Greenfield barrier to entry; deters new un-scaled market entrants [cite: 10] |
Customer contracts feature multi-year terms with implicit auto-renewal structures [cite: 8]. Operational integration is deep; transitioning away from Elis requires clients to reinstall linen inventories, adjust logistics workflows, and re-tag employee garments, introducing operational friction and potential service disruption [cite: 10].
Industrial laundering is fundamentally a fixed-cost operation requiring large-scale machinery, water treatment infrastructure, and specialized delivery fleets [cite: 10]. Elis's network density allows its delivery fleet to service multiple adjacent customers on a single route, lowering logistics expenses per unit [cite: 10]. A new entrant cannot match this cost structure without equivalent local market share [cite: 10]. Furthermore, establishing an industrial-scale laundry hub requires multi-million-euro capital commitments, regulatory environmental permits, and wastewater treatment infrastructure, which deters greenfield competitors and leaves consolidation via targeted M&A as the primary route for market expansion [cite: 7, 10, 11].
The addressable market for commercial textile rental, hygiene, and cleanroom services across Europe and Latin America exceeds €30 billion [cite: 1, 3]. Structural growth is driven by a steady shift from self-managed, in-house laundry operations to professional outsourcing [cite: 1, 11]. Outsourcing penetration remains uneven across geography and industry: while European healthcare and hospitality markets feature high adoption, the workwear, cleanroom, and pest control segments in Southern Europe, Central Europe, and Latin America remain under-penetrated [cite: 1, 6, 12].
Long-term expansion drivers include stringent European mandates governing water usage, microplastic filtration, and carbon intensity, which compel enterprises to abandon inefficient on-premises laundries in favor of Elis's circular economy model [cite: 6, 7]. Expanding pest control, floor care, and cleanroom offerings to existing flat linen and workwear clients increases average revenue per account with minimal incremental logistics expense [cite: 1].
The global textile and facility services industry is bifurcated between regional pan-European leaders and North American providers [cite: 10, 13, 14].
| Competitor | Primary Markets | Positioning vs. Elis SA |
|---|---|---|
| Cintas Corporation | North America | Dominant US market leader; higher valuation multiple profile [cite: 10] |
| Vestis / Aramark | North America | Primary US competitor; undergoing operational restructuring [cite: 10] |
| Rentokil Initial | Global / Europe | Primary peer in commercial hygiene, mats, and pest control services [cite: 1] |
| Regional Operators | Local Markets | Fragmented regional providers; prime targets for Elis bolt-on acquisitions [cite: 7, 11] |
Elis is the undisputed market leader in Europe and Latin America [cite: 6, 14]. While Cintas and Vestis dominate the North American market [cite: 10], Elis maintains leading positions in France, Southern Europe, Scandinavia, and Brazil [cite: 2, 6]. The market remains highly fragmented at the regional level, enabling Elis to execute a systematic strategy of bolt-on acquisitions that consolidate route density and drive operating synergies [cite: 6, 7, 11].
Elis reported its consolidated financial results for the first half of 2026 on July 29, 2026 [cite: 7]. The company demonstrated organic top-line growth and stable operating margins despite macroeconomic sluggishness in parts of Europe and a specific public healthcare contract realignment in Latin America [cite: 7, 15].
| Financial Metric (€ millions) | H1 2026 Reported | H1 2025 Reported | YoY Growth (%) |
|---|---|---|---|
| Revenue | €2,457.1 | €2,343.1 | +4.9% |
| Organic Revenue Growth | +3.2% | +4.3% | -110 bps |
| Adjusted EBITDA | €853.8 | €813.8 | +4.9% |
| Adjusted EBITDA Margin | 34.7% | 34.7% | Flat |
| Adjusted EBIT | €370.0 | €353.8 | +4.6% |
| Adjusted EBIT Margin | 15.1% | 15.1% | Flat |
| Net Income | €163.6 | €152.4 | +7.3% |
| Headline Diluted EPS | €0.89 EUR | €0.85 EUR | +5.1% |
| Free Cash Flow | -€30.1 | +€31.0 | Seasonality / CapEx timing [cite: 7, 8, 16] |
| Net Financial Debt | €3,670.0 | €3,200.0 | Post-buyback completion [cite: 7, 16] |
| Financial Leverage Ratio | 2.09x | 1.92x | +17 bps [cite: 7, 8] |
During H1 2026, total revenue reached €2,457.1 million, representing a 4.9% year-on-year increase on a reported basis [cite: 7]. Organic revenue expanded by 3.2%, supported by price adjustments to offset labor cost inflation, continuous investments in the sales force, and new contract wins in workwear [cite: 6, 7, 15]. External growth (M&A) contributed +1.0% to growth, while foreign exchange provided a +0.2% tailwind [cite: 6].
Adjusted EBITDA rose 4.9% to €853.8 million, with the adjusted EBITDA margin remaining flat at 34.7% [cite: 7]. Margin expansion in European geographies offset localized profitability pressures in Latin America, where volumes were impacted by a public tender launched following the reorganization of Mexico’s federal healthcare system [cite: 7]. Adjusted EBIT reached €370.0 million (+4.6% YoY), maintaining a stable EBIT margin of 15.1% [cite: 7].
Net income expanded by 7.3% to €163.6 million, while headline diluted net income per share increased 5.1% to €0.89 EUR [cite: 7]. Free cash flow for H1 2026 stood at -€30.1 million, reflecting typical seasonal working capital build and timing effects of major laundry plant capital expenditures, which management expects to normalize over the full year [cite: 7, 16]. Net financial debt reached €3,670 million, moving financial leverage to 2.09x as of June 30, 2026, following the completion of a €500 million share buyback program on July 9, 2026 [cite: 7, 16].
| Region (€ millions) | H1 2026 Revenue | Reported Growth | Organic Growth | Operating Performance Context |
|---|---|---|---|---|
| France | €700.0 | +2.5% | +2.0% | Solid commercial momentum in workwear pricing [cite: 6] |
| Central Europe | €645.0 | +4.6% | +2.5% | M&A benefits offset weak German industrial production [cite: 6, 15] |
| Scandinavia & East | €330.0 | +3.8% | +1.4% | Outperformance in Finland, Norway, and Baltics [cite: 6] |
| UK & Ireland | €280.0 | -1.5% | +1.6% | Cleanroom wins offset by adverse foreign exchange [cite: 6] |
| Latin America | €250.0 | +12.6% | +9.5% | Strong Mexican contract rollouts; tender pressure [cite: 6, 7] |
| Southern Europe | €235.0 | +7.9% | +5.2% | Robust demand in travel and hospitality sectors [cite: 6] |
| Total Group | €2,457.1 | +4.9% | +3.2% | Consistent performance across global network [cite: 7] |
Top-line performance across major operating regions reflected varying macroeconomic backdrops. France delivered solid organic growth driven by price adjustments and sales force momentum in workwear [cite: 6]. Central Europe benefited from commercial acquisitions, though core industrial activity in Germany remained subdued [cite: 6, 15]. Scandinavia & Eastern Europe maintained steady growth supported by strong performance in Finland, Norway, and the Baltics [cite: 6]. UK & Ireland achieved positive organic growth driven by cleanroom wins, though currency movements weighed on reported revenue [cite: 6]. Latin America posted high organic growth driven by contract rollouts in Mexico, though margins faced pressure from healthcare tender realignments [cite: 6, 7, 17]. Southern Europe demonstrated robust performance supported by vibrant travel and hospitality activity [cite: 6].
To evaluate financial continuity, full-year 2025 results (announced March 11, 2026) established historical performance benchmarks [cite: 11].
| Financial Metric | FY2025 Actual | FY2024 Restated | YoY Change (%) |
|---|---|---|---|
| Revenue | €4,796.8 million | €4,567.8 million | +4.9% (+3.8% Organic) [cite: 11, 18] |
| Adjusted EBITDA | €1,700.1 million | €1,609.8 million | +5.6% [cite: 11] |
| Adjusted EBITDA Margin | 35.4% | 35.2% | +20 bps [cite: 11] |
| Adjusted EBIT | €766.6 million | €732.9 million | +4.6% [cite: 11] |
| Adjusted EBIT Margin | 16.0% | 16.0% | Flat [cite: 11] |
| Headline Net Income | €467.3 million | €446.3 million | +4.7% [cite: 11, 19] |
| Diluted Headline EPS | €1.85 EUR | €1.76 EUR | +5.2% [cite: 11, 19] |
| Free Cash Flow | €358.6 million | €346.5 million | +3.5% [cite: 11] |
| Year-End Financial Leverage | 1.75x | 1.85x | -0.10x [cite: 11] |
Full-year 2025 revenue reached €4,796.8 million, while adjusted EBITDA totaled €1,700.1 million [cite: 11]. Adjusted EBIT stood at €766.6 million, and free cash flow reached a record €358.6 million [cite: 11]. Leverage declined to 1.75x prior to the execution of the 2026 share buyback initiative [cite: 11].
Management reconfirmed its full-year 2026 financial guidance [cite: 6, 7]:
Management emphasized that record commercial contract signings in H1 2026 provide clear line-of-sight for organic growth acceleration in H2 2026 and FY2027, as client onboardings typically require a 3-to-4 month operational lag before generating billable revenue [cite: 1, 15]. Furthermore, energy costs are hedged for gas and electricity across 2026 and 2027, securing cost reductions [cite: 11, 19].
Following the H1 2026 release, the share price experienced short-term consolidation around €21.26–€21.82 due to margin compression in Latin America and macro weakness in French and German industrial production [cite: 15, 17, 20, 21]. However, sell-side equity research analysts maintained a constructive outlook [cite: 17, 22]:
| Investment Bank | Rating | Price Target (€) | Revision Date / Action Context |
|---|---|---|---|
| Morgan Stanley | Buy | €31.50 EUR | Reconfirmed May 2026; high conviction [cite: 17] |
| UBS | Buy | €29.40 EUR | Reconfirmed July 2026 following earnings [cite: 17] |
| JPMorgan | Buy | €28.20 EUR | Reconfirmed August 2026 [cite: 17] |
| RBC Capital | Outperform | €28.00 EUR | Upgraded August 2026 on FY27 organic outlook [cite: 17, 22] |
| Consensus Target | Strong Buy | €29.79 EUR | Average target across 15 covering analysts [cite: 17] |
Consensus coverage features 15 Buy ratings and 0 Sell ratings, with an average 12-month target price of €29.79 EUR, implying ~40% upside from current trading levels [cite: 17, 22].
At the current trading price of ~€21.32 EUR per share, Elis trades at discounted relative valuation multiples compared to global commercial service peers [cite: 17, 21].
| Valuation Metric | Elis SA (ELIS.PA) | Peer Group Average | Sector Average | Multiples Discount Analysis |
|---|---|---|---|---|
| Trailing P/E | 12.1x | 22.4x | 11.6x | Discount to commercial service peers [cite: 17] |
| Forward P/E | 9.97x | 18.5x | 12.0x | Under 10x forward earnings [cite: 21] |
| EV / EBITDA | 6.27x | 12.5x | 8.5x | Material discount to US peers [cite: 16, 17] |
| Price / LTM Sales | 0.90x | 0.70x | 1.20x | Reflects recurring revenue profile [cite: 17] |
| Price / Book | 1.30x | 2.20x | 1.40x | Supported by tangible asset base [cite: 17] |
| Dividend Yield | 2.26% | 1.80% | 2.10% | Fully covered by free cash flow [cite: 11, 17] |
The current enterprise valuation (~€9.49 billion Enterprise Value on €1.7 billion FY2025 EBITDA) reflects an EV/EBITDA multiple of 6.27x [cite: 2, 16]. This discount relative to US peers like Cintas (EV/EBITDA >20x) is driven by European equity market discount factors and leverage perceptions [cite: 16, 17]. However, Elis's cash conversion, recurring customer base, and ROCE (14.7%) indicate potential for multiple expansion as leverage remains managed within target bands [cite: 1, 11, 18].
Evaluating the business model requires examining structural risk factors across company-specific execution, competitive dynamics, customer demand, regulations, balance sheet management, and macroeconomic sensitivities [cite: 6, 7, 10, 15].
| Risk Category | Key Operational Risk Factor | Strategic Impact & Sensitivity |
|---|---|---|
| Company Execution | Public contract tender losses | Temporary plant capacity underutilization and margin drag [cite: 7, 17] |
| Competitive Dynamics | Regional price discounting | Price realization pressure in mature northern markets [cite: 6] |
| Demand Concentration | Hospitality cyclicality | Occupancy drops impact high-margin flat linen volume [cite: 6, 7, 9, 15] |
| Regulatory & Legal | Environmental & labor mandates | CapEx for wastewater filtration; wage cost inflation [cite: 6, 7, 10] |
| Capital Allocation | Debt refinancing costs | Higher net interest expenses upon refinancing legacy debt [cite: 2, 16] |
| Risk Escalation Tier | Scenario Description | Core Metrics to Monitor |
|---|---|---|
| What Could Go Wrong | European stagflation paired with energy shocks and wage growth | Unadjusted cost inflation suppressing operating margins [cite: 6, 7, 15] |
| Early Warning Sign | Organic growth dropping below inflation rates & extended DSO | DSO expansion, contract delays, elevated customer churn [cite: 6, 15, 16] |
| Structural Thesis Damage | Loss of pricing power and sustained decay in ROCE (<10%) | EBITDA margins declining below 32%; leverage >3.0x [cite: 1, 11, 18] |
Persistent economic stagflation across France and Germany, combined with secondary energy shocks and wage inflation, represents the primary macro risk if Elis is unable to fully pass cost increases to clients through price indexation [cite: 6, 7, 15]. Early warning signs of thesis deterioration include organic revenue growth falling below ambient inflation rates, expanding Days Sales Outstanding (DSO), rising customer churn rates in core workwear, or delays in onboarding new contracts [cite: 6, 15, 16]. Structural thesis damage would occur if loss of pricing power led to multi-year erosion of adjusted EBITDA margins below 32%, structural decline in pre-tax ROCE below 10% (from 14.7%), or net financial leverage exceeding 3.0x on a sustained basis [cite: 1, 11, 18].
The 5-year valuation model evaluates Elis SA over the projection horizon from 2026 through FY2031, using a current base share price of €21.32 EUR [cite: 17].
| Model Parameter | Base Case | High Case | Low Case |
|---|---|---|---|
| 5-Year Sales Growth CAGR | 4.8% | 7.2% | 1.8% |
| Year 5 (FY2031) Revenue | €6,080.0 million | €6,800.0 million | €5,240.0 million |
| FY2031 EBITDA Margin | 36.2% | 37.5% | 33.5% |
| FY2031 Adjusted EBITDA | €2,201.0 million | €2,550.0 million | €1,755.4 million |
| FY2031 Adjusted EBIT Margin | 16.5% | 18.0% | 13.8% |
| FY2031 Net Income | €550.0 million | €730.0 million | €370.0 million |
| FY2031 Fully Diluted Share Count | 200.0 million | 190.0 million | 215.0 million |
| FY2031 EPS | €2.75 EUR | €3.84 EUR | €1.72 EUR |
| Exit P/E Multiple Assumption | 14.0x | 15.0x | 10.5x |
| Implied Target Price (FY2031) | €38.50 EUR | €57.60 EUR | €18.00 EUR |
| Cumulative Dividend Yield Contribution | 12.0% | 15.0% | 8.0% |
| 5-Year Capital Appreciation | +80.6% | +170.2% | -15.6% |
| 5-Year Total Return | +92.6% | +185.2% | -7.6% |
| Annualized Total Return (CAGR) | +14.0% | +23.3% | -1.6% |
| Probability Weight | 60.0% | 25.0% | 15.0% |
Organic revenue growth averages 3.5% per annum, supplemented by 1.3% annual growth from disciplined bolt-on acquisitions [cite: 6, 11]. Densification of European delivery routes and expansion of pest control and cleanroom offerings expand EBITDA margins by 80 bps over 5 years to 36.2% [cite: 1, 11]. Revenue grows from €4,796.8M in FY2025 to €6,080.0M in FY2031 [cite: 11]. Net income reaches €550.0M, while the share count decreases to 200.0 million due to share repurchases financed by cash flow [cite: 7, 11]. EPS grows to €2.75 EUR. Applying a 14.0x exit P/E multiple yields a 2031 share price of €38.50 EUR. Capital appreciation equals +80.6%, and total return including cumulative dividends (~12.0%) reaches +92.6%, representing an annualized return of +14.0%.
Acceleration in outsourcing adoption across Latin America and Southern Europe propels organic growth to 5.2%, with bolt-on M&A adding 2.0% annually [cite: 1, 6, 12]. Cross-selling scales effectively, expanding EBITDA margins to 37.5% and EBIT margins to 18.0% [cite: 1, 11]. FY2031 revenue reaches €6,800.0M, generating €730.0M in net income. Diluted share count declines to 190.0 million shares, resulting in an EPS of €3.84 EUR. The valuation multiple expands to 15.0x P/E, resulting in a target share price of €57.60 EUR. Capital gain equals +170.2%, and total return with dividends reaches +185.2% (+23.3% annualized).
European economic stagnation and persistent wage inflation constrain growth [cite: 6, 15]. Organic growth averages 1.0%, while M&A activity slows [cite: 6]. Increased price sensitivity and lost public tenders reduce EBITDA margins to 33.5% [cite: 6, 7]. Revenue slowly rises to €5,240.0M by FY2031. Net income settles at €370.0M on a share count of 215.0 million, resulting in an EPS of €1.72 EUR. The valuation multiple compresses to 10.5x P/E, resulting in a target share price of €18.00 EUR. Capital returns equal -15.6%, partially cushioned by dividends, yielding a net total return of -7.6% (-1.6% annualized).
| Scenario | Current Price | Year 1 (2027) | Year 2 (2028) | Year 3 (2029) | Year 4 (2030) | Year 5 (2031) |
|---|---|---|---|---|---|---|
| Base Case | €21.32 EUR | €23.80 EUR | €26.80 EUR | €30.20 EUR | €34.00 EUR | €38.50 EUR |
| High Case | €21.32 EUR | €26.00 EUR | €31.80 EUR | €38.90 EUR | €47.50 EUR | €57.60 EUR |
| Low Case | €21.32 EUR | €20.50 EUR | €19.80 EUR | €19.20 EUR | €18.60 EUR | €18.00 EUR |
$\text{Weighted Price Target} = (0.60 \times €38.50) + (0.25 \times €57.60) + (0.15 \times €18.00)$
$\text{Weighted Price Target} = €23.10 + €14.40 + €2.70 = \mathbf{€40.20\text{ EUR}}$
The probability-weighted target price of €40.20 EUR implies a potential 5-year upside of +88.6% relative to the current share price of €21.32 EUR [cite: 17].
| Scenario | Revenue / key scale metric in Year 5 | Margin / earnings assumption | Valuation multiple assumption | Current share price | Implied future share price | 5-year total return | Annualized return | Probability |
|---|---|---|---|---|---|---|---|---|
| Base Case | €6,080.0M Revenue | 36.2% EBITDA / EPS €2.75 | 14.0x P/E (7.5x EV/EBITDA) | €21.32 EUR | €38.50 EUR | +92.6% | +14.0% | 60.0% |
| High Case | €6,800.0M Revenue | 37.5% EBITDA / EPS €3.84 | 15.0x P/E (8.5x EV/EBITDA) | €21.32 EUR | €57.60 EUR | +185.2% | +23.3% | 25.0% |
| Low Case | €5,240.0M Revenue | 33.5% EBITDA / EPS €1.72 | 10.5x P/E (5.5x EV/EBITDA) | €21.32 EUR | €18.00 EUR | -7.6% | -1.6% | 15.0% |
COMPOUNDING VALUE ACCRETION
| Evaluated Metric | Score (1–10) | Qualitative Evaluation & Primary Narrative Justification |
|---|---|---|
| Management Alignment | 8 / 10 | Compensation is tied to organic growth, ROCE, and free cash flow targets [cite: 23, 24]. Regular employee share plans ("Elis for All") align staff interests with equity performance [cite: 25, 26]. |
| Revenue Quality | 9 / 10 | Over 70% of revenue is contractually recurring under multi-year agreements with inflation indexation clauses that secure cash flow predictability [cite: 6, 8, 11]. |
| Market Position | 9 / 10 | Unrivaled scale in Europe and Latin America [cite: 6, 14]. Market leadership creates route density advantages that present hurdles for regional competitors [cite: 10]. |
| Growth Outlook | 7 / 10 | Structural growth in outsourcing and cross-selling in cleanroom/pest control provides steady mid-single-digit expansion, constrained by mature European markets [cite: 1, 6]. |
| Financial Health | 8 / 10 | Maintained investment-grade credit status (S&P BBB- positive outlook) [cite: 1]. Strong free cash flow (~€358M in 2025) supports deleveraging while funding growth CapEx [cite: 1, 11]. |
| Business Viability | 9 / 10 | Essential operational provider for healthcare hygiene, pharmaceutical cleanrooms, and hospitality infrastructure, presenting low risk of obsolescence [cite: 1, 7, 9]. |
| Capital Allocation | 8 / 10 | Management maintains a balanced capital allocation strategy, combining bolt-on M&A, steady dividend growth (€0.48/share for 2025), and share repurchases [cite: 7, 11]. |
| Analyst Sentiment | 9 / 10 | Strong sell-side consensus, with unanimous Buy/Outperform ratings and target prices ranging between €28.00 and €31.50 EUR [cite: 17, 22]. |
| Profitability | 9 / 10 | High operating margins relative to peers (35.4% adjusted EBITDA margin), supported by vertical integration and laundering efficiency [cite: 10, 11]. Pre-tax ROCE reached 14.7% in 2025 [cite: 11, 18]. |
| Track Record | 8 / 10 | Proven ability to integrate acquisitions (such as Berendsen) and navigate cost inflation through pricing discipline [cite: 11, 14]. |
| Blended Score | 8.4 / 10 | Overall qualitative assessment reflecting robust business model durability. |
EXCEPTIONAL OPERATIONAL MOAT
Elis SA presents a compounding business profile characterized by market leadership, contractually recurring revenue, and strong geographic route density across Europe and Latin America [cite: 6, 8, 10]. The company operates a circular service model that aligns with corporate sustainability directives and operational efficiency trends [cite: 6, 7].
Key growth catalysts include:
Principal risks center on macroeconomic weakness in core European industrial markets, inflation in labor and energy costs, integration risks from bolt-on M&A, and public contract tender dynamics [cite: 6, 7, 10, 15]. At current valuation levels (~12.1x trailing P/E and 6.27x EV/EBITDA), the market reflects a discount relative to the company's historical financial performance, cash flow generation, and consensus price target upside (~€29.79 EUR) [cite: 16, 17, 21].
UNDERVALUED COMPOUNDING LEADER
Trading at €21.32 EUR, Elis SA is currently positioned -15.36% below its 200-day simple moving average (~€25.18 EUR) and -24.98% below its 52-week high of €28.34 EUR [cite: 17, 21]. The equity experienced price consolidation following the H1 2026 results release due to localized margin headwinds in Latin America and macro weakness in German and French manufacturing [cite: 7, 15, 21]. Short-term technical momentum displays oversold conditions, with solid structural support forming around the €20.88–€21.00 level [cite: 17, 21]. Capital structure catalysts—including the completion of the €500 million share buyback and the early redemption of the 2029 OCEANEs convertible bond series in October 2026—provide potential near-term support for market positioning [cite: 7, 21, 25].
OVERSOLD TACTICAL SETUP
View Elis SA (ELIS.PA) stock page
Loading the interactive version of this report…